发明名称 METHODS FOR CHARACTERIZING AND TREATING ACUTE MYELOID LEUKEMIA
摘要 The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.
申请公布号 US2017080102(A1) 申请公布日期 2017.03.23
申请号 US201515311632 申请日期 2015.05.19
申请人 ImmunoGen, Inc. 发明人 Whiteman Kathleen R.;Noordhuis Paul;Kovtun Yelena;Lutz Robert J.;Schuurhuis Gerrit Jan;Walker Russell Marlin
分类号 A61K39/00;C12Q1/68;A61K31/5517;G01N33/574 主分类号 A61K39/00
代理机构 代理人
主权项 1. A method of treating acute myeloid leukemia in a subject, the method comprising administering an effective amount of an immunoconjugate to a pre-selected subject, wherein the immunoconjugate comprises a humanized or chimeric antibody or fragment thereof conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker represented by the following structural formula:wherein the antibody comprises a heavy chain variable region comprising one or more complementarity determining regions selected from the group consisting of SEQ ID NOs: 1-3; and/or a light chain variable region comprising one or more complementarity determining regions selected from the group consisting of SEQ ID NOs: 4-6; and the cytotoxic benzodiazepine dimer compound represented by one of the following structural formulas or a pharmaceutically acceptable salt thereof:wherein Y is —SO3M and M is H or a pharmaceutically acceptable cation and wherein the pre-selection comprises detecting CD33 in a biological sample of the subject.
地址 Waltham MA US